Can Jisandai (Bingtonsha) treat hepatitis C virus completely?

Epclusa (Epclusa), this oral antiviral drug, has shown remarkable results in the treatment of chronic hepatitis C virus (HCV) infection. It consists of two ingredients: Sofosbuvir (Sofosbuvir) and Velpatasvir (Velpatasvir). The former is used as NS5Bpolymerase inhibitor, which acts as an NS5A inhibitor. The two work synergistically to inhibit the replication and spread of hepatitis C virus. It is worth mentioning that Jisandai (Bingtonsa) is currently the only hepatitis C drug that is not restricted by viral genotypes and is approved for the treatment of all six genotypes of HCV.

In clinical trials, the performance of Jisandai (Bingtonsha) is impressive. The cure rate (SVR12), that is, the proportion of patients whose hepatitis C virusRNA cannot be detected after completing 12 weeks of treatment, is as high as 95% or more. This data fully proves the excellent effect of Jisandai (Bingtongsha) in eliminating hepatitis C virus. However, whether hepatitis C virus can be completely eliminated is still affected by many factors.

Factors such as the patient's degree of liver cirrhosis, viral load, previous treatment history, and comorbidities may affect the therapeutic effect of Jisandai (Bingtonsha). For example, patients with more severe cirrhosis may have a relatively low cure rate, while patients with better liver function are more likely to achieve complete viral clearance. In addition, some special circumstances, such as patients who are resistant to drugs or have other underlying diseases, may also have a certain impact on the efficacy of Jisandai (Bingtonsha).

The usage of Jisandai (Bingtonsha) is relatively simple. Take one tablet once a day for 12 consecutive weeks. For patients with decompensated cirrhosis, Bintonsa should be used in combination with ribavirin (Ribavirin) to improve the therapeutic effect. During treatment, patients should undergo regular blood tests to monitor changes in viral load and liver function, and make necessary adjustments to the treatment plan under the guidance of a doctor.